千红制药(002550) - 2020 Q3 - 季度财报

Financial Performance - Operating revenue for the reporting period was ¥508,351,298.61, an increase of 68.71% year-on-year[8]. - Net profit attributable to shareholders was ¥82,501,011.13, up 78.40% compared to the same period last year[8]. - Net profit attributable to shareholders after deducting non-recurring gains and losses was ¥76,739,648.29, an increase of 171.57% year-on-year[8]. - Basic earnings per share for the reporting period were ¥0.0662, an increase of 72.85% year-on-year[8]. - The operating profit for the period was CNY 93,495,749.10, up from CNY 47,013,879.73, reflecting a growth of approximately 98.8%[80]. - The net profit reached CNY 78,875,505.14, compared to CNY 41,592,149.04 in the previous year, marking an increase of around 89.5%[80]. - Net profit for the current period was ¥90,584,493.54, up from ¥54,219,264.86 in the previous period, reflecting a significant increase[88]. - The total comprehensive income for the current period was ¥90,584,493.54, compared to ¥54,219,264.86 in the previous period[90]. - The total profit for the current period was ¥174,849,767.47, down from ¥257,279,810.40 in the previous period, a decline of about 32.0%[100]. Cash Flow - Net cash flow from operating activities was ¥170,531,335.99, representing a 113.40% increase compared to the previous year[8]. - The cash and cash equivalents at the end of the reporting period increased by 111.65% compared to the beginning of the year, primarily due to the maturity of financial products during the reporting period[22]. - Operating cash flow from operating activities amounted to ¥220,896,211.71, an increase of 61.5% compared to ¥136,704,095.40 in the previous period[107]. - Total cash inflow from operating activities was ¥1,328,085,353.24, while total cash outflow was ¥1,107,244,719.28, resulting in a net cash flow of ¥220,840,633.96[114]. - The net increase in cash and cash equivalents was ¥227,631,514.83, compared to a decrease of -¥110,049,383.07 in the previous period[110]. Assets and Liabilities - Total assets at the end of the reporting period were ¥2,666,128,210.21, a decrease of 9.14% compared to the end of the previous year[8]. - The total liabilities decreased significantly to ¥320,433,950.71 from ¥601,649,743.32, a reduction of 46.80%[62]. - The total current assets amounted to ¥1,862,831,455.94, a decrease of approximately 10.84% from ¥2,089,313,004.41 on December 31, 2019[56]. - The total non-current assets were reported at ¥803,296,754.27, a decline of 4.93% from ¥844,974,062.85[59]. - The total equity attributable to shareholders increased to ¥2,354,384,111.38 from ¥2,331,861,745.64, reflecting a growth of 0.96%[64]. Shareholder Information - The total number of shareholders at the end of the reporting period was 54,358[12]. - The largest shareholder, Wang Yaofang, held 19.96% of the shares, totaling 255,402,000 shares[12]. Research and Development - The development expenditure at the end of the reporting period grew by 142.35% compared to the beginning of the year, attributed to ongoing investments in R&D projects[26]. - Research and development expenses were CNY 15,238,782.86, down from CNY 21,676,549.66, indicating a decrease of approximately 29.8%[77]. - Research and development expenses decreased to ¥7,813,970.30 from ¥11,011,266.24 in the previous period, showing a reduction in R&D spending[83]. - Research and development expenses for the current period were ¥23,582,146.45, down from ¥33,320,461.24 in the previous period, indicating a reduction of approximately 29.2%[101]. Financial Management - The company reported no significant non-recurring gains or losses that would be classified as regular gains or losses[11]. - The company experienced a significant decline in financial product income, which decreased by 84.53% year-on-year, and foreign exchange gains fell by 214.13% compared to the previous year[22]. - The company's financial expenses increased by 101.62 million yuan compared to the same period last year, mainly due to reduced income from financial products and reclassification under financial instrument accounting standards[34]. - The company reported a financial expense of CNY 12,218,250.09, compared to a financial income of CNY 31,191,170.90 in the previous period, reflecting a significant shift in financial performance[77]. - The company incurred interest expenses of ¥7,512,616.90 in the current period, down from ¥14,744,328.48 in the previous period, a decrease of about 49.1%[100]. Inventory and Receivables - The company’s inventory increased to ¥255,662,667.59, up from ¥245,864,287.12, indicating a growth of 3.25%[56]. - Accounts receivable decreased to ¥326,061,624.56, down 23.25% from ¥424,978,680.70[56].